COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,705 Articles (22,913 medRxiv, 8,792 bioRxiv)

Most recent first Previous |  Page 1116: Articles 11151-11160  | Next

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Saliba, C., Bowen, J. E., Rosen, L. E., Culap, K., Pinto, D., De Marco, A., Zepeda, S. K., di Iulio, J., Zatta, F., Kaiser, H., Noack, J., Farhat, N., Czudnochowski, N., Havenar-Daughton, C., Sprouse, K. R., Dillen, J. R., Powell, A. E., Chen, A., Maher, C., Yin, L., Sun, D., Soriaga, L., Gustafsson, C., Chu, H., Franko, N. M., Logue, J., Iqbal, N. T., Mazzitelli, I., Geffner, J., Grifantini, R., Gori, A., Riva, A., Giannini, O., Ceschi, A., Ferrari, P., Franzetti-Pellanda, A., Garzoni, C., Hebner, C., Purcell, L., Piccoli, L., Pizzuto, M. S., Walls, A. C., Telenti, A., Virgin, H. W., Lanzavecchia, A., Veesler, D., Snell, G., Corti, D.
10.1101/2021.12.12.472269 — Posted: 2021-12-14
Assessing impact of Omicron on SARS-CoV-2 dynamics and public health burden
Le Rutte, E. A., Shattock, A. J., Chitnis, N., Kelly, S. L., Penny, M. A.
10.1101/2021.12.12.21267673 — Posted: 2021-12-14
Scanning the RBD-ACE2 molecular interactions in Omicron variant
Rath, S. L., Padhi, A. K., Mandal, N.
10.1101/2021.12.12.472253 — Posted: 2021-12-14
Language Models for the Prediction of SARS-CoV-2 Inhibitors
Blanchard, A. E., Gounley, J., Bhowmik, D., Chandra Shekar, M., Lyngaas, I., Gao, S., Yin, J., Tsaris, A., Wang, F., Glaser, J.
10.1101/2021.12.10.471928 — Posted: 2021-12-14
TopHap: Rapid inference of key phylogenetic structures from common haplotypes in large genome collections with limited diversity
Caraballo-Ortiz, M. A., Miura, S., Sanderford, M., Dolker, T., Tao, Q., Weaver, S., Kosakovsky Pond, S. L., Kumar, S.
10.1101/2021.12.13.472454 — Posted: 2021-12-14
Analysis: A meta-analysis of Early Results to predict Vaccine efficacy against Omicron
Khoury, D. S., Steain, M., Triccas, J., Sigal, A., Davenport, M. P., Cromer, D.
10.1101/2021.12.13.21267748 — Posted: 2021-12-14
SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies
Ikemura, N., Hoshino, A., Higuchi, Y., Taminishi, S., Inaba, T., Matoba, S.
10.1101/2021.12.13.21267761 — Posted: 2021-12-14
Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses
Liu, L., Iketani, S., Guo, Y., Casner, R., Reddem, E., Nair, M. S., Yu, J., Chan, J., Wang, M., Cerutti, G., Li, Z., Castagna, C., Corredor, L., Chu, H., Yuan, S., Poon, V., Chan, C., Chen, Z., Luo, Y., Cunningham, M., Chavez, A., Yin, M., Perlin, D., Tsuji, M., Yuen, K.-Y., Kwong, P., Sheng, Z., Huang, Y., Shapiro, L., Ho, D. D.
10.1101/2021.12.11.472236 — Posted: 2021-12-14
Mucosal and systemic responses to SARS-CoV-2 vaccination in infection naive and experienced individuals
Sajadi, M. M., Myers, A., Logue, J., Saadat, S., Shokatpour, N., Quinn, J., Newman, M., Deming, M., Tehrani, Z. R., Karimi, M., Abbasi, R., Crotty, S., Harris, A. D.
10.1101/2021.12.13.472159 — Posted: 2021-12-14
CHARM: COVID-19 Health Action Response for Marines - association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test
Sedegah, M., Porter, C., Hollingdale, M. R., Ganeshan, H., Huang, J., Goforth, C. W., Belmonte, M., Belmonte, A., Weir, D. L., Lizewski, R. A., Lizewski, S. E., Sealfon, S. C., Jani, V., Cheng, Y., Inoue, S., Velasco, R., Villasante, E., Sun, P., Letizia, A.
10.1101/2021.12.13.472352 — Posted: 2021-12-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).